RS60129B1 - Kompozicije alfa-galaktozidaze - Google Patents

Kompozicije alfa-galaktozidaze

Info

Publication number
RS60129B1
RS60129B1 RS20200291A RSP20200291A RS60129B1 RS 60129 B1 RS60129 B1 RS 60129B1 RS 20200291 A RS20200291 A RS 20200291A RS P20200291 A RSP20200291 A RS P20200291A RS 60129 B1 RS60129 B1 RS 60129B1
Authority
RS
Serbia
Prior art keywords
galactosidase
alpha
compositions
galactosidase compositions
Prior art date
Application number
RS20200291A
Other languages
English (en)
Inventor
Avidor Shulman
Uri Hanania
Tali Kizhner
Yoseph Shaaltiel
Original Assignee
Protalix Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IL2011/000209 external-priority patent/WO2011107990A1/en
Application filed by Protalix Ltd filed Critical Protalix Ltd
Publication of RS60129B1 publication Critical patent/RS60129B1/sr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2465Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/47Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52Genes encoding for enzymes or proenzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
RS20200291A 2011-01-20 2011-09-07 Kompozicije alfa-galaktozidaze RS60129B1 (sr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161434499P 2011-01-20 2011-01-20
US201161434503P 2011-01-20 2011-01-20
PCT/IL2011/000209 WO2011107990A1 (en) 2010-03-02 2011-03-02 Stabilized alpha-galactosidase and uses thereof
EP17164713.4A EP3272861B1 (en) 2011-01-20 2011-09-07 Alpha-galactosidase compositions

Publications (1)

Publication Number Publication Date
RS60129B1 true RS60129B1 (sr) 2020-05-29

Family

ID=44786043

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20200291A RS60129B1 (sr) 2011-01-20 2011-09-07 Kompozicije alfa-galaktozidaze

Country Status (18)

Country Link
US (1) US9732333B2 (sr)
EP (2) EP3272861B1 (sr)
JP (1) JP5913372B2 (sr)
KR (1) KR101883803B1 (sr)
CN (1) CN103443270B (sr)
AU (1) AU2011356137A1 (sr)
BR (1) BR112013018516B1 (sr)
CA (1) CA2824791A1 (sr)
CY (1) CY1122794T1 (sr)
DK (2) DK3272861T3 (sr)
ES (1) ES2774190T3 (sr)
IL (1) IL227552B (sr)
LT (1) LT3272861T (sr)
PL (1) PL3272861T3 (sr)
PT (1) PT3272861T (sr)
RS (1) RS60129B1 (sr)
SI (1) SI3272861T1 (sr)
WO (1) WO2012098537A1 (sr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2696699A1 (en) 2007-08-20 2009-02-26 Protalix Ltd. Saccharide-containing protein conjugates and uses thereof
US9194011B2 (en) 2009-11-17 2015-11-24 Protalix Ltd. Stabilized alpha-galactosidase and uses thereof
JP5913372B2 (ja) 2011-01-20 2016-04-27 プロタリクス リミテッド 植物および植物細胞におけるα−ガラクトシダーゼの発現のための核酸発現構築物
US20160017021A1 (en) * 2013-03-06 2016-01-21 Protalix Ltd. TNF alpha INHIBITOR POLYPEPTIDES, POLYNUCLEOTIDES ENCODING SAME, CELLS EXPRESSING SAME AND METHODS OF PRODUCING SAME
AU2014224174B2 (en) * 2013-03-06 2018-08-30 Hadasit Medical Research Services And Development Ltd. Use of plant cells expressing a TNFalpha polypeptide inhibitor in therapy
TWI642782B (zh) * 2013-10-23 2018-12-01 健臻公司 重組醣蛋白及其用途
KR20170124549A (ko) 2015-03-17 2017-11-10 그리노파티온 바이오테크 게엠베하 글리코실화된 리소좀 단백질, 생산 방법 및 용도
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
WO2018127920A1 (en) * 2017-01-05 2018-07-12 Protalix Ltd. Therapeutic regimen for the treatment of fabry using stabilized alpha-galactosidase
IL257269A (en) * 2018-01-31 2018-04-09 Olender Tsviya Signaling is directed to the endoplasmic reticulum
KR102209198B1 (ko) * 2019-04-02 2021-02-02 주식회사 바이오앱 식물에서의 발현이 최적화된 재조합 이리신 유전자 및 이를 이용한 재조합 이리신 단백질의 생산 방법
KR102213745B1 (ko) 2019-04-16 2021-02-09 주식회사 바이오앱 돼지 유행성 설사병 바이러스 백신 조성물 및 이의 제조 방법
WO2020256372A1 (ko) 2019-06-17 2020-12-24 주식회사 바이오앱 아프리카 돼지열병의 진단을 위한 항원 생산용 재조합 벡터 및 이의 용도
WO2023027402A1 (ko) 2021-08-27 2023-03-02 주식회사 바이오앱 아프리카 돼지열병 바이러스 유래 항원 단백질을 포함하는 아프리카 돼지열병의 예방용 백신

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
CA1192510A (en) 1981-05-27 1985-08-27 Lawrence E. Pelcher Rna plant virus vector or portion thereof, a method of construction thereof, and a method of producing a gene derived product therefrom
JPS6054684A (ja) 1983-09-05 1985-03-29 Teijin Ltd 新規dνa及びハイブリツドdνa
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
CA1288073C (en) 1985-03-07 1991-08-27 Paul G. Ahlquist Rna transformation vector
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
GB8608850D0 (en) 1986-04-11 1986-05-14 Diatech Ltd Packaging system
JPS6314693A (ja) 1986-07-04 1988-01-21 Sumitomo Chem Co Ltd 植物ウイルスrnaベクタ−
EP0278667B1 (en) 1987-02-09 1994-07-20 Mycogen Plant Science, Inc. Hybrid RNA virus
US5316931A (en) 1988-02-26 1994-05-31 Biosource Genetics Corp. Plant viral vectors having heterologous subgenomic promoters for systemic expression of foreign genes
US6846968B1 (en) * 1988-02-26 2005-01-25 Large Scale Biology Corporation Production of lysosomal enzymes in plants by transient expression
US5693507A (en) 1988-09-26 1997-12-02 Auburn University Genetic engineering of plant chloroplasts
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5614587A (en) 1988-11-21 1997-03-25 Collagen Corporation Collagen-based bioadhesive compositions
US5936035A (en) 1988-11-21 1999-08-10 Cohesion Technologies, Inc. Biocompatible adhesive compositions
US5179023A (en) 1989-03-24 1993-01-12 Research Corporation Technologies, Inc. Recombinant α-galactosidase a therapy for Fabry disease
US5302523A (en) 1989-06-21 1994-04-12 Zeneca Limited Transformation of plant cells
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
DE4009630C2 (de) 1990-03-26 1995-09-28 Reinhard Prof Dr Dr Brossmer CMP-aktivierte fluoreszierende Sialinsäuren sowie Verfahren zu ihrer Herstellung
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US5401650A (en) 1990-10-24 1995-03-28 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-galactosidase A
UA48104C2 (uk) 1991-10-04 2002-08-15 Новартіс Аг Фрагмент днк, який містить послідовність,що кодує інсектицидний протеїн, оптимізовану для кукурудзи,фрагмент днк, який забезпечує направлену бажану для серцевини стебла експресію зв'язаного з нею структурного гена в рослині, фрагмент днк, який забезпечує специфічну для пилку експресію зв`язаного з нею структурного гена в рослині, рекомбінантна молекула днк, спосіб одержання оптимізованої для кукурудзи кодуючої послідовності інсектицидного протеїну, спосіб захисту рослин кукурудзи щонайменше від однієї комахи-шкідника
WO1993018148A2 (en) 1992-03-12 1993-09-16 Wisnieski Bernadine J Tumor necrosis factor with modified channel activity
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
CA2144319A1 (en) 1993-07-09 1995-01-19 George N. Cox Recombinant ctla4 polypeptides and methods for making the same
US6329191B1 (en) 1993-08-30 2001-12-11 Hawaii Biotechnology Group, Inc. DNA encoding recombinant coffee bean alpha-galactosidase
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5994086A (en) 1994-03-30 1999-11-30 North Shore University Hospital Method for assessing infertility by binding of mannose to sperm cells
CA2211417A1 (en) 1995-01-30 1996-08-08 New York Blood Center, Inc. Recombinant .alpha.-galactosidase enzyme
ES2326705T3 (es) 1995-09-14 2009-10-16 Virginia Tech Intellectual Properties, Inc. Produccion de enzimas lisosomicas en sistemas de expresion basados en plantas.
US6309646B1 (en) 1996-05-09 2001-10-30 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Protein-polysaccharide conjugate vaccines and other immunological reagents prepared using homobifunctional and heterobifunctional vinylsulfones, and processes for preparing the conjugates
US6083725A (en) 1996-09-13 2000-07-04 Transkaryotic Therapies, Inc. Tranfected human cells expressing human α-galactosidase A protein
IL119310A (en) 1996-09-26 1999-07-14 Metabogal Ltd Cell/tissue culturing device and method
US20050032211A1 (en) 1996-09-26 2005-02-10 Metabogal Ltd. Cell/tissue culturing device, system and method
IL155588A0 (en) 2003-04-27 2003-11-23 Metabogal Ltd Methods for expression of enzymatically active recombinant lysosomal enzymes in transgenic plant root cells and vectors used thereby
US20010008766A1 (en) 1998-03-17 2001-07-19 Sylvia Daunert Quantitative binding assays using green fluorescent protein as a label
IL125423A (en) 1998-07-20 2004-08-31 Israel State Alkaline alpha-galactosidase having broad substrate specificity
AR025984A1 (es) 1999-10-07 2002-12-26 Maxygen Aps Polipeptidos oligomericos de cadena simple
US7244823B2 (en) 2000-03-02 2007-07-17 Xencor TNF-alpha variants proteins for the treatment of TNF-alpha related disorders
US20070172449A1 (en) 2000-03-02 2007-07-26 Xencor, Inc. TNF-alpha VARIANT FORMULATIONS FOR THE TREATMENT OF TNF-alpha RELATED DISORDERS
US7687461B2 (en) 2000-03-02 2010-03-30 Xencor, Inc. Treatment of TNF-α related disorders with TNF-α variant proteins
US7001994B2 (en) 2001-01-18 2006-02-21 Genzyme Corporation Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins
US7723296B2 (en) 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
CA2435037A1 (en) 2001-01-18 2002-07-25 Silke Schumacher Bifunctional fusion proteins with glucocerebrosidase activity
PL369606A1 (en) 2001-10-22 2005-05-02 Applied Research Systems Ars Holding N.V. Gonadotrophins for folliculogenesis
CA2467052A1 (en) 2001-11-16 2003-05-22 Pharmexa A/S Immunogenic mimetics of multimer proteins with promiscuous t cell epitope inserts
AU2003228722B2 (en) 2002-04-25 2009-06-25 Takeda Pharmaceutical Company Limited Treatment of alpha-galactosidase A deficiency
CA2427190A1 (en) * 2002-04-30 2003-10-30 Alberta Research Council Inc. Production of recombinant epidermal growth factor in plants
DE60330779D1 (de) 2002-05-15 2010-02-11 Agricultural Res Org Für alkalische a-galactosidasen codierende polynukleotidsequenzen und verfahren zur verwendung davon
US20050176108A1 (en) 2003-03-13 2005-08-11 Young-Min Kim Physiologically active polypeptide conjugate having prolonged in vivo half-life
EP1613264A4 (en) 2003-04-16 2007-08-15 Yeda Res & Dev MEDICAMENT FOR THE TREATMENT OF GAUCHER DISEASE AND METHOD FOR IDENTIFYING IT
US7951557B2 (en) 2003-04-27 2011-05-31 Protalix Ltd. Human lysosomal proteins from plant cell culture
GB2402677A (en) 2003-05-06 2004-12-15 Sirus Pharmaceuticals Ltd Biodegradable polymer
EP1639085A2 (en) 2003-06-12 2006-03-29 Genzyme Corporation Modified human acid sphingomyelinase having increased activity, and methods for making the same
JP2005043317A (ja) 2003-07-25 2005-02-17 Olympus Corp 糖鎖と生体分子との反応を検出する方法
US7442372B2 (en) 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
CA2545276C (en) 2003-11-05 2016-05-31 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Carbohydrate antigen-nanoparticle conjugates and uses thereof as antimetastatic agents in treating cancer
JP2007515410A (ja) 2003-12-03 2007-06-14 ネオス テクノロジーズ インコーポレイテッド GlycoPEG化卵胞刺激ホルモン
AU2005211775B2 (en) 2004-02-06 2009-10-08 Biomarin Pharmaceutical Inc. Manufacture of highly phosphorylated lysosomal enzymes and uses thereof
WO2006093524A2 (en) 2004-07-16 2006-09-08 The General Hospital Corporation Antigen-carbohydrate conjugates
EP1877099B1 (en) 2005-04-06 2012-09-19 Genzyme Corporation Therapeutic conjugates comprising a lysosomal enzyme, polysialic acid and a targeting moiety
US20110070201A1 (en) 2005-07-18 2011-03-24 Protalix Ltd. Mucosal or enteral administration of biologically active macromolecules
KR20070065157A (ko) 2005-12-19 2007-06-22 이수근 고객맞춤형 투자자산 관리기능을 갖는 인터넷뱅킹 시스템및 방법
WO2008012525A1 (en) 2006-07-25 2008-01-31 Lipoxen Technologies Limited Derivatisation of granulocyte colony-stimulating factor
EP2121005A1 (en) 2006-12-21 2009-11-25 Academisch Ziekenhuis bij de Universiteit van Amsterdam Treatment of fabry disease
DK2457920T3 (en) 2007-01-18 2018-01-22 Genzyme Corp Oligosaccharides comprising an amino oxy group and conjugates thereof
EP1955712A1 (en) 2007-02-09 2008-08-13 Scil proteins GmbH Multimeric conjugate
EP3366762B1 (en) 2007-05-07 2020-07-08 Protalix Ltd. Large scale disposable bioreactor
WO2008157263A2 (en) 2007-06-15 2008-12-24 Arkansas State University Methods of delivery of molecules to cells using a ricin subunit and compositions relating to same
CA2696699A1 (en) 2007-08-20 2009-02-26 Protalix Ltd. Saccharide-containing protein conjugates and uses thereof
EP2339951A1 (en) 2008-07-10 2011-07-06 Given Imaging Ltd. Device, method and kit for in vivo detection of a biomarker
WO2011061736A1 (en) 2009-11-17 2011-05-26 Protalix Ltd. Alkaline alpha galactosidase for the treatment of fabry disease
US9194011B2 (en) 2009-11-17 2015-11-24 Protalix Ltd. Stabilized alpha-galactosidase and uses thereof
EP2542572B1 (en) 2010-03-02 2015-05-06 Protalix Ltd. Multimeric forms of therapeutic proteins and uses thereof
PL2865751T3 (pl) * 2010-03-02 2017-03-31 Protalix Ltd Stabilizowana alfa-galaktozydaza i jej zastosowania
JP5913372B2 (ja) 2011-01-20 2016-04-27 プロタリクス リミテッド 植物および植物細胞におけるα−ガラクトシダーゼの発現のための核酸発現構築物

Also Published As

Publication number Publication date
BR112013018516A2 (pt) 2019-05-21
PL3272861T3 (pl) 2020-07-13
DK2665814T3 (en) 2017-09-11
BR112013018516B1 (pt) 2023-11-07
IL227552B (en) 2018-05-31
IL227552A0 (en) 2013-09-30
CA2824791A1 (en) 2012-07-26
EP2665814A1 (en) 2013-11-27
EP3272861B1 (en) 2019-12-18
JP2014506450A (ja) 2014-03-17
US9732333B2 (en) 2017-08-15
EP3272861A1 (en) 2018-01-24
KR20140015330A (ko) 2014-02-06
ES2774190T3 (es) 2020-07-17
JP5913372B2 (ja) 2016-04-27
WO2012098537A1 (en) 2012-07-26
KR101883803B1 (ko) 2018-07-31
DK3272861T3 (da) 2020-03-23
CN103443270A (zh) 2013-12-11
WO2012098537A8 (en) 2013-08-08
AU2011356137A1 (en) 2013-08-15
CY1122794T1 (el) 2021-05-05
SI3272861T1 (sl) 2020-06-30
US20130295065A1 (en) 2013-11-07
CN103443270B (zh) 2017-06-06
LT3272861T (lt) 2020-03-25
PT3272861T (pt) 2020-03-26
EP2665814B1 (en) 2017-05-17

Similar Documents

Publication Publication Date Title
HK1203403A1 (en) Peracid-generating compositions
PL2736491T3 (pl) Kompozycje bepotastyny
PL3272861T3 (pl) Kompozycje alfa- galaktozydazy
GB201117619D0 (en) Compositions
SG11201401335QA (en) Compositions
GB201117621D0 (en) Compositions
EP2730619A4 (en) COMPOSITION
EP2763756A4 (en) BROMOFLUOROCARBON COMPOSITIONS
EP2692796A4 (en) COMPOSITION
GB2496447B (en) Compositions
GB201110833D0 (en) Compositions
GB201103942D0 (en) Compositions
HK1201687A1 (en) Improved compositions
ZA201400260B (en) Surfactant compositions
GB201110132D0 (en) compositions
GB201104849D0 (en) Compositions
EP2711011A4 (en) PANAXADIUM-CONTAINING COMPOSITION
GB201122213D0 (en) Compositions
GB201122214D0 (en) Compositions
GB201122216D0 (en) Compositions
GB201121028D0 (en) Compositions
GB201120406D0 (en) Compositions
GB201117234D0 (en) Compositions
GB201117165D0 (en) Compositions
GB201114629D0 (en) Compositions